« Back to report listing





Number of Pages:95

super report icon

US Targeted Therapeutics Market Analysis

Detailed Market Forecast 2010-2013


The Targeted Therapeutics Market Analysis report provides valuable insights and access to the competitive information influencing the direction of the targeted therapies market from 2010-2013. PharmaPeek has divided the report by therapy class for quick reference and included revenue analysis along with a very detailed product analysis. This report is saturated with information highlighting the targeted therapy market.


Cancer is the second leading cause of death in the United States. Even though there have been many advances in detection and treatment of cancer, the disease is yet to be cured. Cancer is defined as a group of cells that display uncontrolled growth (division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These abnormal cells start invading the nearby healthy cells leading to their destruction which later impacts the functioning of the organ. In advanced stages, cancer cells can migrate to nearby organs or to any organ in the body through blood or lymph system, thereby impacting those organs too. Cancer is often detected when it has reached advanced stages, putting additional pressure on treatment options.

Targeted therapy is a relatively new therapeutic option for treating cancer. It involves the use of either monoclonal antibody or small molecules, which target specific areas of the cancerous cells that are important for cell function. These drugs usually inhibit specific proteins which eventually lead to cell death. The death of the cancer cells is achieved without, or by minimally affecting, the healthy cells.

Targeted Therapeutics Market Analysis

In 2008, the targeted cancer therapeutics market was estimated to be valued at $9.83 billion. This market is forecasted to grow at a healthy growth rate of 14.2 percent over the forecast period, 2008 to 2013. By the end of forecast period, 2013, the targeted therapeutics market is expected to be worth $19.14 billion.

The targeted drugs can be monoclonal antibodies or small molecules. They are further classified on the basis of the target they inhibit. Some of the key segments of targeted therapeutics considered in this study are tyrosine kinase inhibitors, such as epidermal growth factor receptor (EGFR) inhibitors and human epidermal receptor (HER), angiogenesis inhibitor or vascular endothelial growth factor receptor (VEGFR) inhibitor, proteasome inhibitors, immunotherapy, multiple tyrosine kinase inhibitors and mTOR inhibitors. Currently, VEGFR inhibitor is the largest segment in this market and its only drug, Avastin, by Genentech / Roche, is responsible for the whole revenues from this segment. Closely following the footsteps of VEGFR inhibitors is the immunotherapy segment. The sales of this segment are mainly driven by Genentech / Roche’s Rituxan. Multiple tyrosine kinase inhibitors and HER-2 inhibitors follow the immunotherapy agents. The newer classes of targeted therapeutics such as proteasome inhibitors and mTOR inhibitors are yet to make a huge impact on the market. In 2013, the market share and ranking of these classes are likely to change due to increased pipeline potential of multiple tyrosine kinase inhibitors and EGFR inhibitors.


  • Chapter 1: Introduction to Cancer
    • Types of Cancer
    • Cancer Treatment Options
    • Types of Cancer Based on Site of Occurrence
  • Chapter 2: Introduction to Targeted Therapy
    • Classes of Targeted Therapy
      • Tyrosine Kinase Receptor Inhibitors (TKI)
      • Angiogenesis Inhibitors
      • Proteasome Inhibitors
      • Immunotherapy
      • Multiple Tyrosine Kinase Inhibitors
      • mTOR inhibitors
  • Chapter 3: Revenue Analysis
    • Targeted Therapy Market Overview
      • Drivers for the targeted therapeutics market
      • Restraints for the targeted therapeutics market
      • Challenges faced by the targeted therapeutics drugs market
    • Targeted Therapeutics Market Analysis
    • Revenue Analysis by Segment
    • VEGFR inhibitors
    • Immunotherapy
    • EGFR inhibitors
    • HER-2 inhibitors
    • Multiple Tyrosine Kinase Inhibitor
    • mTOR inhibitors
    • Other Classes
  • Chapter 4: Competitive Analysis
    • Product Analysis
    • Market Share Analysis
    • Top 5 targeted drugs according to the revenues generated in the United States
  • Chapter 5: Product Analysis
    • Avastin (bevacizumab)
    • Rituxan
    • Herceptin (trastuzumab)
    • Tarceva (erlotinib)
    • Afinitor (Everolimus)
    • Gleevec (Imatinib)
    • Nexavar (Sorafenib)
    • Erbitux (cetuximab)
    • Sutent (sunitinib)
    • Velcade (bortezomib)
    • Tykerb (lapatanib)
    • Campath (alemtuzumab)
  • Chapter 6: Pipeline Analysis Overview
    • Targeted Therapeutics Market: Approved drugs pipeline, by development phase


  • Roche/Genentech
  • Novartis
  • Pfizer
  • Wyeth
  • Genzyme
  • Bristol Myers Squibb
  • Imclone
  • Eli Lilly
  • Biogen Idec
  • Medarex
  • Amgen
  • Bayer
  • Onyx
  • GSK
  • AstraZeneca
  • Takeda
  • Genmab
  • Millennium
  • Merck
  • RIT Oncology
  • Spectrum
  • Chephalon
  • Celgene
  • Dr. Reddy's
  • OSI
  • Teva
  • Mylan
  • Johnson and Johnson PRD


  • Avastin
  • Rituxan
  • Tarceva
  • Afinitor
  • Axitinib
  • Bosutinib
  • Bexxar
  • Campath
  • Certican
  • Cevarix
  • Erbitux
  • Figitumumab
  • GA101
  • Galiximab
  • Getfitinib
  • Gleevec
  • Glivec
  • HSP90 inhibitor
  • Herceptin
  • IMC-1121B
  • IMC-11F8
  • ipilimumab
  • Ixempra
  • Lumiliximab
  • Lucentis
  • MLN0518
  • Motesanib
  • Neratinib
  • Nexavar
  • Ofatumumab
  • Pazopanib
  • Tykerb
  • Pertuzumab
  • Recentin
  • Revlimid
  • Rituxan
  • Ridaforolimus
  • Saracatinib
  • Sprycel
  • Sutent
  • Tarceva
  • Tasigna
  • Torisel
  • Treanda
  • Tykerb
  • Vectibix
  • Velcade
  • Volociximab
  • Votrient
  • Zactima
  • Zalutumumab
  • Zevalin
  • ZD4054
  • Zometa
  • Zactima
  • Xeloda